Stock Events

Stock Events

AIM ImmunoTech 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MayExpected
Q4 2025
Next
-1.21
-0.91
-0.61
-0.32
Expected EPS
-0.315536
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HXB.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap19.09B
Incyte Corporation operates in the biopharmaceutical field focusing on the discovery, development, and commercialization of proprietary therapeutics, including those that affect the immune system's function, which competes with AIM's immunotherapy approaches.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need, including treatments that modulate the immune system, directly competing with AIM's product pipeline.
Moderna
MRNA
Mkt Cap19.51B
Moderna, Inc. focuses on mRNA-based therapies, some of which are designed to activate the immune system against cancer and infectious diseases, competing with AIM's immunotherapeutic strategies.
BioNTech
BNTX
Mkt Cap22.92B
BioNTech SE operates in the field of mRNA technology and immunotherapy, developing treatments that stimulate the body's immune response, similar to AIM's focus, making them direct competitors in the immunotherapy space.
Novavax
NVAX
Mkt Cap1.25B
Novavax, Inc. is involved in the development of vaccines that stimulate the immune system, competing with AIM ImmunoTech's efforts in immune system modulation for disease prevention and treatment.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals, Inc. is known for its innovation in biotechnology, including the development of immune-modulating drugs, which places it in direct competition with AIM in the field of immunotherapies.
Cytodyn
CYDY
Mkt Cap343.01M
CytoDyn Inc. focuses on the development and commercialization of novel therapeutics for the treatment of immune, viral, and other serious diseases, competing with AIM's focus on immune-based therapies.
iBio
IBIO
Mkt Cap68.4M
iBio, Inc. is a biotechnology company that focuses on developing plant-based biopharmaceuticals, including vaccines and therapeutic proteins that modulate the immune system, making it a competitor to AIM in the broader field of immune-based therapies.

About

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Show more...
CEO
Mr. Thomas K. Equels Esq., J.D., M.S.
Employees
21
Country
United Kingdom
ISIN
US00901B3033

Listings

LSE
GB
0A4Y.LSE
F
DE
HXB.F
OTCM
US
AIMI
MU
DE
HXB.MU

0 Comments

Share your thoughts

FAQ

What is AIM ImmunoTech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange AIM ImmunoTech stocks are traded under the ticker HXB.STU.
When is the next AIM ImmunoTech earnings date?▼
AIM ImmunoTech is going to release the next earnings report on May 14, 2026.
What were AIM ImmunoTech earnings last quarter?▼
HXB.STU earnings for the last quarter are -1.21 EUR per share, whereas the estimation was -0.82 EUR resulting in a -48.02% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does AIM ImmunoTech have?▼
As of April 12, 2026, the company has 21 employees.
In which sector is AIM ImmunoTech located?▼
AIM ImmunoTech operates in the Energy sector.
When did AIM ImmunoTech complete a stock split?▼
AIM ImmunoTech has not had any recent stock splits.
Where is AIM ImmunoTech headquartered?▼
AIM ImmunoTech is headquartered in Ocala, United Kingdom.